|
1) Joyce DE, Gelbert L, Ciaccia A, et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem. 2001; 276: 11199-203
|
|
|
|
2) Franscini N, Bachli EB, Blau N, et al. Gene expression profiling of inflamed human endothelial cells and influence of activated protein C. Circulation. 2004; 110: 2903-9
|
|
|
|
|
|
3) Riewald M, Ruf W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem. 2005; 280: 19808-14
|
|
|
|
|
|
4) Riewald M, Petrovan RJ, Donner A, et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002; 296: 1880-2
|
|
|
|
|
|
5) Niessen F, Schaffner F, Furlan-Freguia C, et al. Dendritic cell PAR1-S1P3 signaling couples coagulation and inflammation. Nature. 2008; 452: 654-8
|
|
|
|
|
|
6) Bae JS, Yang L, Manithody C, et al. The ligand occupancy of endothelial protein C receptor switches the protease-activated receptor 1-dependent signaling specificity of thrombin from a permeability-enhancing to a barrier-protective response in endothelial cells. Blood. 2007; 110: 3909-16
|
|
|
|
|
|
7) Schuepbach RA, Feistritzer C, Brass LF, et al. Activated protein C-cleaved protease activated receptor-1 is retained on the endothelial cell surface even in the presence of thrombin. Blood. 2008; 111: 2667-73
|
|
|
|
|
|
8) Niessen F, Furlan-Freguia C, Fernandez JA, et al. Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood. 2009; 113: 2859-66
|
|
|
|
|
|
9) Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol. 2005; 5: 560-70
|
|
|
|
|
|
10) Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005; 105: 3178-84
|
|
|
|
|
|
11) Singleton PA, Moreno-Vinasco L, Sammani S, et al. Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation. Am J Respir Cell Mol Biol. 2007; 37: 222-31
|
|
|
|
|
|
12) Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nat Rev Immunol. 2005; 5: 617-28
|
|
|
|
|
|
13) Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007; 7: 19-30
|
|
|
|
|
|
14) Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007; 449: 419-26
|
|
|
|
|
|
15) Esmon C. Do-all receptor takes on coagulation, inflammation. Nat Med. 2005; 11: 475-7
|
|
|
|
|
|
16) Tracey KJ. The inflammatory reflex. Nature. 2002; 420: 853-9
|
|
|
|
|
|
17) Abeyama K, Stern DM, Ito Y, et al. The N- terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism. J Clin Invest. 2005; 115: 1267-74
|
|
|
|
|
|
18) Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappa B and mitogen-activated protein kinase pathways. J Exp Med. 2002; 196: 565-77
|
|
|
|
|
|
19) Kaneider NC, Leger AJ, Agarwal A, et al. ʻRole reversalʼ for the receptor PAR1 in sepsis-induced vascular damage. Nat Immunol. 2007; 8: 1303-12
|
|
|
|
|
|
20) Han MH, Hwang SI, Roy DB, et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature. 2008; 451: 1076-81
|
|
|
|
|
|
21) Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007; 13: 1349-58
|
|
|
|
|